Cancer-associated thromboembolism: could direct-acting oral anticoagulants be a promising therapeutic option? Literature review
Cancer-associated thromboembolism (CAT) is usually managed with low-molecular-weight heparins (LMWHs) or vitamin K antagonists (VKAs). The recent data suggest that direct-acting oral anticoagulants (DOACs) might have a role in the management of CAT both in terms of prevention and treatment. The aim...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2020-09-01
|
Series: | Forum of Clinical Oncology |
Subjects: | |
Online Access: | https://doi.org/10.2478/fco-2019-0009 |